Amy Bachrodt, SVP, Finance at Maze Therapeutics, Inc. (MAZE), sold 2,500 shares at $29.32 ($74K) on 2026-04-01, disclosed to the SEC on 2026-04-02.
Scheduled sale ($74k) by SVP, Finance under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.32 | 2,200 | $65K | 87.6% |
| 2 | $30.34 | 300 | $9K | 12.4% |
| Total | $29.44 avg | 2,500 | $74K | 100% |
| Filing → |
| MAZE | SELL | 2026-01-26 | $455K | — | Filing → |
| MAZE | SELL | 2026-01-06 | $392K | — | Filing → |
| MAZE | SELL | 2025-12-31 | $606K | — | Filing → |